Skip to main content
Top
Published in:

03-01-2024 | Splenectomy | ORIGINAL ARTICLE

Establishment of Prognosis Nomogram for Primary Splenic Diffuse Large B Cell Lymphoma: A Study Based on SEER Database

Authors: Ouyang Yonghao, Wei Yongyang, Yi Siqing, Fu Chengchao, Chu Lihua, Liu xin, Tu Shuju

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 2/2024

Login to get access

Abstract

Despite being the most common primary tumor of the spleen, in the past, few studies have predicted the prognosis of primary spleen diffuse large B cell lymphoma. This study aimed to establish a nomogram prediction model of overall survival in primary DLBCL of the spleen. We screened out 347 patients with primary splenic DLBCL from surveillance, epidemiology, and end results database. According to the Cox regression results (age, Ann Arbor Stage, splenectomy and chemotherapy was the independent risk factor for primary splenic DLBCL), the nomogram was constructed. We evaluated the predictive ability of nomogram with C-Index (training cohort: 0.719 [0.669–0.769]; validation cohort: 0.711 [0.641–0.781]) and 3-year/5-year receiver operating characteristic area under curve (3-year/5-year ROCAUC, training cohort: 0.731/0.742; validation cohort: 0.721/0.742). Calibratioin plot shows that our predicted values fluctuate around the actual value, indicating good agreement with nomogram. The decision curve analysis (DCA) results showed that our nomogram could benefit more than Ann Arbor Stage for predicts the prognosis of the primary splenic DLBCL. The Kaplan–Meier and landmark analysis showed that a great discrimination between high-risk group and low-risk group (P < 0.05) and indicating that our nomogram has the good ability to identify high-risk patients. In this study, a nomogram prediction model for primary spleen DLBCL was established, which has good ability of prediction and generalization. It can help clinicians carry out individualized treatment measures.
Literature
1.
2.
go back to reference Kashimura M, Noro M, Akikusa B et al (2008) Primary splenic diffuse large B-cell lymphoma manifesting in red pulp. Virchows Arch 453(5):501–509CrossRefPubMed Kashimura M, Noro M, Akikusa B et al (2008) Primary splenic diffuse large B-cell lymphoma manifesting in red pulp. Virchows Arch 453(5):501–509CrossRefPubMed
3.
go back to reference Ahmann DL, Kiely JM, Harrison EG Jr, Payne WS (1966) Malignant lymphoma of the spleen. A review of 49 cases in which the diagnosis was made at splenectomy. Cancer 19(4):461–469CrossRefPubMed Ahmann DL, Kiely JM, Harrison EG Jr, Payne WS (1966) Malignant lymphoma of the spleen. A review of 49 cases in which the diagnosis was made at splenectomy. Cancer 19(4):461–469CrossRefPubMed
4.
go back to reference Yu SC, Lin CW (2013) Early-stage splenic diffuse large B-cell lymphoma is highly associated with hepatitis C virus infection. Kaohsiung J Med Sci 29(3):150–156CrossRefPubMed Yu SC, Lin CW (2013) Early-stage splenic diffuse large B-cell lymphoma is highly associated with hepatitis C virus infection. Kaohsiung J Med Sci 29(3):150–156CrossRefPubMed
5.
go back to reference Shimono J, Miyoshi H, Arakawa F et al (2019) Clinicopathological features of HCV-positive splenic diffuse large B cell lymphoma. Ann Hematol 98(5):1197–1207CrossRefPubMed Shimono J, Miyoshi H, Arakawa F et al (2019) Clinicopathological features of HCV-positive splenic diffuse large B cell lymphoma. Ann Hematol 98(5):1197–1207CrossRefPubMed
6.
go back to reference Mollejo M, Algara P, Mateo MS et al (2003) Large B-cell lymphoma presenting in the spleen: identification of different clinicopathologic conditions. Am J Surg Pathol 27(7):895–902CrossRefPubMed Mollejo M, Algara P, Mateo MS et al (2003) Large B-cell lymphoma presenting in the spleen: identification of different clinicopathologic conditions. Am J Surg Pathol 27(7):895–902CrossRefPubMed
7.
go back to reference Bairey O, Shvidel L, Perry C et al (2015) Characteristics of primary splenic diffuse large B-cell lymphoma and role of splenectomy in improving survival. Cancer 121(17):2909–2916CrossRefPubMed Bairey O, Shvidel L, Perry C et al (2015) Characteristics of primary splenic diffuse large B-cell lymphoma and role of splenectomy in improving survival. Cancer 121(17):2909–2916CrossRefPubMed
8.
go back to reference Shimono J, Miyoshi H, Kiyasu J et al (2017) Clinicopathological analysis of primary splenic diffuse large B-cell lymphoma. Br J Haematol 178(5):719–727CrossRefPubMed Shimono J, Miyoshi H, Kiyasu J et al (2017) Clinicopathological analysis of primary splenic diffuse large B-cell lymphoma. Br J Haematol 178(5):719–727CrossRefPubMed
9.
10.
go back to reference Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA (2013) Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol 87(2):146–171CrossRefPubMed Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA (2013) Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol 87(2):146–171CrossRefPubMed
11.
go back to reference Abid MB, Nasim F, Anwar K, Pervez S (2005) Diffuse large B cell lymphoma (DLBCL) in Pakistan: an emerging epidemic? Asian Pac J Cancer Prev 6(4):531–534PubMed Abid MB, Nasim F, Anwar K, Pervez S (2005) Diffuse large B cell lymphoma (DLBCL) in Pakistan: an emerging epidemic? Asian Pac J Cancer Prev 6(4):531–534PubMed
12.
go back to reference Dasgupta T, Coombes B, Brasfield RD (1965) Primary Malignant Neoplasms of the Spleen. Surg Gynecol Obstet 120:947–960PubMed Dasgupta T, Coombes B, Brasfield RD (1965) Primary Malignant Neoplasms of the Spleen. Surg Gynecol Obstet 120:947–960PubMed
13.
go back to reference Kehoe J, Straus DJ (1988) Primary lymphoma of the spleen. Clinical features and outcome after splenectomy. Cancer 62(7):1433–1438CrossRefPubMed Kehoe J, Straus DJ (1988) Primary lymphoma of the spleen. Clinical features and outcome after splenectomy. Cancer 62(7):1433–1438CrossRefPubMed
14.
go back to reference Shi Y, Han Y, Yang J et al (2019) Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: analysis of 1,085 WHO classified cases in a single institution in China. Chin J Cancer Res 31(1):152–161CrossRefPubMedPubMedCentral Shi Y, Han Y, Yang J et al (2019) Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: analysis of 1,085 WHO classified cases in a single institution in China. Chin J Cancer Res 31(1):152–161CrossRefPubMedPubMedCentral
15.
go back to reference Dachman AH, Buck JL, Krishnan J, Aguilera NS, Buetow PC (1998) Primary non-Hodgkin’s splenic lymphoma. Clin Radiol 53(2):137–142CrossRefPubMed Dachman AH, Buck JL, Krishnan J, Aguilera NS, Buetow PC (1998) Primary non-Hodgkin’s splenic lymphoma. Clin Radiol 53(2):137–142CrossRefPubMed
16.
go back to reference Kim JK, Hahn JS, Kim GE, Yang WI (2005) Three cases of diffuse large B-cell lymphoma presenting as primary splenic lymphoma. Yonsei Med J 46(5):703–709CrossRefPubMedPubMedCentral Kim JK, Hahn JS, Kim GE, Yang WI (2005) Three cases of diffuse large B-cell lymphoma presenting as primary splenic lymphoma. Yonsei Med J 46(5):703–709CrossRefPubMedPubMedCentral
17.
go back to reference Solbiati L, Bossi MC, Bellotti E, Ravetto C, Montali G (1983) Focal lesions in the spleen: sonographic patterns and guided biopsy. AJR Am J Roentgenol 140(1):59–65CrossRefPubMed Solbiati L, Bossi MC, Bellotti E, Ravetto C, Montali G (1983) Focal lesions in the spleen: sonographic patterns and guided biopsy. AJR Am J Roentgenol 140(1):59–65CrossRefPubMed
18.
19.
go back to reference Shen Z, Wang L, Zhang B et al (2021) Development and validation of a novel prognostic nomogram for CD5-positive diffuse large B-cell lymphoma: a retrospective multicenter study in China. Front Oncol 11:754180CrossRefPubMedPubMedCentral Shen Z, Wang L, Zhang B et al (2021) Development and validation of a novel prognostic nomogram for CD5-positive diffuse large B-cell lymphoma: a retrospective multicenter study in China. Front Oncol 11:754180CrossRefPubMedPubMedCentral
20.
go back to reference Jiang S, Qin Y, Liu P et al (2020) Prognostic nomogram and predictive factors in refractory or relapsed diffuse large B-cell lymphoma patients failing front-line R-CHOP regimens. J Cancer 11(6):1516–1524CrossRefPubMedPubMedCentral Jiang S, Qin Y, Liu P et al (2020) Prognostic nomogram and predictive factors in refractory or relapsed diffuse large B-cell lymphoma patients failing front-line R-CHOP regimens. J Cancer 11(6):1516–1524CrossRefPubMedPubMedCentral
21.
go back to reference Han Y, Yang J, Liu P et al (2019) Prognostic nomogram for overall survival in patients with diffuse large B-cell lymphoma. Oncologist 24(11):e1251–e1261CrossRefPubMedPubMedCentral Han Y, Yang J, Liu P et al (2019) Prognostic nomogram for overall survival in patients with diffuse large B-cell lymphoma. Oncologist 24(11):e1251–e1261CrossRefPubMedPubMedCentral
22.
go back to reference Chen DB, Shen DH, Zhang H et al (2017) Tumors of lymphoid and hematopoietic tissue of spleen a clinicopathologic analysis of 53 cases. Zhonghua Bing Li Xue Za Zhi=Chin J Pathol 46(11):775–781 Chen DB, Shen DH, Zhang H et al (2017) Tumors of lymphoid and hematopoietic tissue of spleen a clinicopathologic analysis of 53 cases. Zhonghua Bing Li Xue Za Zhi=Chin J Pathol 46(11):775–781
Metadata
Title
Establishment of Prognosis Nomogram for Primary Splenic Diffuse Large B Cell Lymphoma: A Study Based on SEER Database
Authors
Ouyang Yonghao
Wei Yongyang
Yi Siqing
Fu Chengchao
Chu Lihua
Liu xin
Tu Shuju
Publication date
03-01-2024
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 2/2024
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-023-01706-6

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

Combining tafasitamab with lenalidomide and rituximab significantly improves progression-free survival for patients with relapsed or refractory follicular lymphoma.

Featuring the official presentation video

Read more
SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now